US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ashland

50.48

+0.93001.88%

Post-market: 50.480.00000.00%16:07 EDT

Volume:404.29K

Turnover:20.42M

Market Cap:2.38B

PE:-110.09

High:50.98

Open:49.91

Low:49.73

Close:49.55

Loading ...

Overview Company News Filings

TScan Therapeutics to present data from ongoing ALLOHA Phase 1 trial at ASH

Regeneron announces new data from odronextamab trial at ASH

Eli Lilly to present Phase 3 results for Jaypirca at ASH meeting

Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Ashland rings opening bell at NYSE recognizes 100-year anniversary

Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Protagonist Therapeutics announces data from REVIVE study at ASH

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

Crispr Therapeutics presents data on CTX112 at ASH Meeting

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ASH/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASH\",,,,,undefined,":{"symbol":"ASH","market":"US","secType":"STK","nameCN":"Ashland","latestPrice":50.48,"timestamp":1744920000000,"preClose":49.55,"halted":0,"volume":404291,"hourTrading":{"tag":"盘后","latestPrice":50.48,"preClose":50.48,"latestTime":"16:07 EDT","volume":15308,"amount":772747.84,"timestamp":1744920471689},"delay":0,"floatShares":46615360,"shares":47182862,"eps":-0.458541,"marketStatus":"Market Closed","change":0.93,"latestTime":"04-17 16:00:00 EDT","open":49.91,"high":50.98,"low":49.725,"amount":20420541.548092,"amplitude":0.025328,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.458541,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":49.55,"dividendRate":0.031696,"preHourTrading":{"tag":"盘前","latestPrice":49.55,"preClose":49.55,"latestTime":"08:02 EDT","volume":10,"amount":492.04998,"timestamp":1744891342185},"postHourTrading":{"tag":"盘后","latestPrice":50.48,"preClose":50.48,"latestTime":"16:07 EDT","volume":15308,"amount":772747.84,"timestamp":1744920471689},"volumeRatio":0.672300055897583,"impliedVol":0.5279,"impliedVolPercentile":0.9562},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASH\",,,,,undefined,":{"symbol":"ASH","floatShares":46615360,"roa":"1.94%","roe":"0.18%","lyrEps":3.448979,"volumeRatio":0.672300055897583,"shares":47182862,"dividePrice":1.6,"high":50.98,"amplitude":0.025328,"preClose":49.55,"low":49.725,"week52Low":45.21,"pbRate":"0.92","psRate":"1.16","week52High":102.5,"institutionHeld":0.8513,"latestPrice":50.48,"eps":-0.458541,"divideRate":0.031696,"volume":404291,"delay":0,"ttmEps":-0.458541,"open":49.91,"prevYearClose":71.46,"prevWeekClose":50.51,"prevMonthClose":59.29,"prevQuarterClose":59.29,"fiveDayClose":48.59,"twentyDayClose":55.87,"sixtyDayClose":70.63,"earningDate":1745942400000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASH\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2490082552","title":"TScan Therapeutics to present data from ongoing ALLOHA Phase 1 trial at ASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2490082552","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490082552?lang=en_us&edition=fundamental","pubTime":"2024-12-10 07:00","pubTimestamp":1733785214,"startTime":"0","endTime":"0","summary":"TScan Therapeutics (TCRX) “announced that updated results from the ongoing ALLOHA Phase 1 trial of TSC-100 and TSC-101 will be presented during an ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tscan-therapeutics-to-present-data-from-ongoing-alloha-phase-1-trial-at-ash?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tscan-therapeutics-to-present-data-from-ongoing-alloha-phase-1-trial-at-ash?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TCRX","BK4539","LU2463526074.USD","LENZ","BK4109","ASH"],"gpt_icon":0},{"id":"2490361082","title":"Regeneron announces new data from odronextamab trial at ASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2490361082","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490361082?lang=en_us&edition=fundamental","pubTime":"2024-12-10 06:55","pubTimestamp":1733784907,"startTime":"0","endTime":"0","summary":"Regeneron (REGN) announced new and updated data for odronextamab were presented at the 66th American Society of Hematology, or ASH, annual meeting ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regeneron-announces-new-data-from-odronextamab-trial-at-ash?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regeneron-announces-new-data-from-odronextamab-trial-at-ash?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1917777945.USD","LU2106854487.HKD","LU0114720955.EUR","LU1974910355.USD","LU0058720904.USD","BK4139","LU0823416689.USD","REGN","LU0289739699.SGD","LU0109394709.USD","BK4109","LU0882574055.USD","LU2023250504.SGD","ASH","LU2362541513.USD","BK4585","LU0053666078.USD","LU2362540622.SGD","LU0889565916.HKD","LU2089984988.USD","LU0320765992.SGD","LU2468319806.SGD","LU2463526074.USD","LU2362541273.HKD","BK4588"],"gpt_icon":0},{"id":"2490084356","title":"Eli Lilly to present Phase 3 results for Jaypirca at ASH meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490084356","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490084356?lang=en_us&edition=fundamental","pubTime":"2024-12-10 06:50","pubTimestamp":1733784607,"startTime":"0","endTime":"0","summary":"Eli Lilly (LLY) and Company announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent Bruton’s tyrosine kinas...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eli-lilly-to-present-phase-3-results-for-jaypirca-at-ash-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eli-lilly-to-present-phase-3-results-for-jaypirca-at-ash-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0096364046.USD","LU0820561818.USD","SG9999014898.SGD","LU0943347566.SGD","LU1127390331.HKD","LU0708995401.HKD","LU2063271972.USD","LU1366192091.USD","BK4581","LU1974910355.USD","LU1988902786.USD","LU1057294990.SGD","LLY","LU1623119135.USD","LU2023250504.SGD","IE00BJLML261.HKD","LU1061106388.HKD","SG9999017495.SGD","LU0882574055.USD","LU1868836757.USD","LU0094547139.USD","LU1291159041.SGD","LU1868837136.USD","LU0385154629.USD","LU2361044865.SGD","SG9999015952.SGD","SGXZ31699556.SGD","LU0466842654.USD","LU2264538146.SGD","LU1267930730.SGD","LU2237443549.SGD","LU2324357040.USD","LU2237443895.HKD","SG9999018865.SGD","LU1093756168.USD","LU0417517546.SGD","SG9999014906.USD","LU0203201768.USD","LU1023059063.AUD","LU1064131342.USD","LU1868836914.USD","SG9999001176.SGD","LU0289739699.SGD","ASH","BK4007","LU1551013342.USD","BK4516","LU1868837300.USD","LU0456855351.SGD"],"gpt_icon":0},{"id":"2490824090","title":"Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490824090","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490824090?lang=en_us&edition=fundamental","pubTime":"2024-12-10 06:45","pubTimestamp":1733784300,"startTime":"0","endTime":"0","summary":"– ZUMA-5 Analysis Shows Median Progression-Free Survival of 62.2 Months and Median Duration of Response of 60.4 Months After Median Follow-Up of More Than Five Years –。– Over Half of Patients Alive at Time of Analysis, with No Need for Subsequent Therapy and Rare Instances of Late Disease Progression, Indicating Curative Potential –。\"Relapsed or refractory non-Hodgkin lymphomas, including follicular lymphoma and marginal zone lymphoma, are generally considered to be incurable, with most patients ultimately relapsing,\" said Dr. Sattva S. Neelapu, lead investigator, The University of Texas MD Anderson Cancer Center. \"These impressive results demonstrate the continued durable clinical benefit and manageable long-term safety profile of axi-cel and give us hope that it may have a curative effect on these difficult-to-treat blood cancers.\". Median progression-free survival  was 62.2 months . PFS rates at 60 months in patients with FL were consistent regardless of high-risk characteristics.\"T","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/RkoDAp7SqsIUuIrO6Pshsw--~B/aD00ODA7dz0xNTk1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7cbd0a95708c813fa6b7eb3c2887f99a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/RkoDAp7SqsIUuIrO6Pshsw--~B/aD00ODA7dz0xNTk1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7cbd0a95708c813fa6b7eb3c2887f99a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kite-yescarta-only-car-t-224500323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","BK4583","BK4532","BK4097","KRG","BK4195","IE00BKVL7J92.USD","IE00B7SZL793.SGD","LU1430594728.SGD","LU1839511570.USD","BK4080","IE0031619046.USD","LU0109394709.USD","LU2468319806.SGD","BK4139","LU1066051498.USD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","LU0058720904.USD","ASH","IE0002270589.USD","BK4022","BK4094","BK4231","BK4109","CAR","IE00BZ1G4Q59.USD","LU1585245621.USD","BK4006","BK4161","IE00B19Z3581.USD","BK4578","BK4230","LU0320765992.SGD","FL","LU0889565916.HKD","OS","LU0234570918.USD","LU0289739699.SGD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","PFS","CRS","GILD","IE00B3T34201.USD","CR","LU2087621335.USD","BK4588","BK4211","BK4550"],"gpt_icon":0},{"id":"2490084828","title":"TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2490084828","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490084828?lang=en_us&edition=fundamental","pubTime":"2024-12-10 06:45","pubTimestamp":1733784300,"startTime":"0","endTime":"0","summary":"To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting toxicities ob","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2994122/0/en/TScan-Therapeutics-to-Present-Updated-Data-from-the-Ongoing-ALLOHA-Phase-1-Heme-Trial-During-Oral-Session-at-the-66th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","LU1571399168.USD","LU1699723380.USD","LU2355687059.USD","ALL","BK4533","LENZ","BK4139","BK4117","BK4109","AFG","BK4585","BK4107","ASH","BK4588","LU2463526074.USD","KOL"],"gpt_icon":0},{"id":"2490898940","title":"Ashland rings opening bell at NYSE recognizes 100-year anniversary","url":"https://stock-news.laohu8.com/highlight/detail?id=2490898940","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490898940?lang=en_us&edition=fundamental","pubTime":"2024-12-10 06:01","pubTimestamp":1733781660,"startTime":"0","endTime":"0","summary":"Company to hold investor strategy update event on December 10, 2024Wilmington, Del., Dec.  09, 2024  (GLOBE NEWSWIRE) -- Participating in a tradition that has evolved since 1792, today, employees from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2994114/0/en/Ashland-rings-opening-bell-at-NYSE-recognizes-100-year-anniversary.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NYSE","BK4109","ESG","ASH","LU2463526074.USD"],"gpt_icon":0},{"id":"2490081050","title":"Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits","url":"https://stock-news.laohu8.com/highlight/detail?id=2490081050","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490081050?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:30","pubTimestamp":1733779800,"startTime":"0","endTime":"0","summary":"– ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, in Bruton Tyrosine Kinase Inhibitor-Nave R/R MCL Patients –。The data presented include an oral presentation  of a primary analysis of ZUMA-2 cohort 3 demonstrating an overall response rate  of 91% and complete response  rate of 73% in Bruton tyrosine kinase inhibitor -nave patients with R/R MCL. Long-term follow-up of patients in ZUMA-2 cohorts 1 and 2 , showed that 39% of patients with R/R MCL were still alive after five years, underscoring Tecartus as the only CAR T to have five-year follow-up data in this patient population. In addition, real-world evidence outcomes in adults with R/R B-ALL treated with Tecartus  demonstrated a high effectiveness and consistent safety profile in a broader patient population than the pivotal ZUMA-3 study.ZUMA-2 is a single-arm, multicenter, open-label Phase 2 study that investigated leukapheresed adult patients  with MCL whose disease is refractory to or has rela","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Iso5L50ClWe0wvVuNEJZMQ--~B/aD00ODA7dz0xNTk1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2ca0a0475617783d9c88977ef644bcb3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Iso5L50ClWe0wvVuNEJZMQ--~B/aD00ODA7dz0xNTk1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2ca0a0475617783d9c88977ef644bcb3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/longest-data-reported-kite-tecartus-213000327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","BK4585","LU0985320562.USD","LU2463526074.USD","BK4022","BK4583","BK4230","CR","LU1585245621.USD","LU1839511570.USD","PD","CRS","IE00B19Z3581.USD","BK4566","BK4097","PR","LU1066051498.USD","ALL","BK4231","LU1169590202.USD","BK4533","PFS","ASH","BK4006","IE00B19Z3B42.SGD","LU0289739699.SGD","IE00BKVL7J92.USD","BK4139","BK4578","LU0234570918.USD","IE00B7SZL793.SGD","IE00B7SZLL34.SGD","IE00B19Z4B17.USD","LU0058720904.USD","CAR","BK4588","GILD","LU2468319806.SGD","BK4568","OS","BK4550","BK4080","LU2355687059.USD","IE00B3T34201.USD","LU0109394709.USD","BK4195","LU1066053197.SGD","KRG","LU0889565916.HKD","LU1571399168.USD"],"gpt_icon":0},{"id":"2490085603","title":"Protagonist Therapeutics announces data from REVIVE study at ASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2490085603","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490085603?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:20","pubTimestamp":1733779259,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) announced details from a poster presentation with final data from the rusfertide Phase 2 REVIVE study. Rusfertide, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-announces-data-from-revive-study-at-ash?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-announces-data-from-revive-study-at-ash?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2463526074.USD","PTGX","BK4139","BK4109","ASH"],"gpt_icon":0},{"id":"2490108307","title":"Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490108307","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490108307?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:05","pubTimestamp":1733778300,"startTime":"0","endTime":"0","summary":"54% of patients experience more than 2.5 years of durable hematocrit  control , decreased phlebotomy use, long-term tolerability, and improvements in patient-reported outcomes in patients with polycythemia vera. NEWARK, CA / ACCESSWIRE / December 9, 2024 / Protagonist Therapeutics, Inc.  announced details from a poster presentation with final data from the rusfertide Phase 2 REVIVE study. Rusfertide, a mimetic of the natural hormone hepcidin, has potential therapeutic value in the treatment of polycythemia vera  and other disease indications. The data were presented at the 66th American Society of Hematology  Annual Meeting and Exposition, taking place December 7-10, 2024. A copy of the presentation will be available on the Events and Presentations section of the Protagonist website.In Part 2 , the EPHL was <1/year and approximately 6.1/year in the rusfertide and placebo groups, respectively.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protagonist-reports-final-results-rusfertide-210500496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BVYPNW00.USD","LU1674673691.USD","LU1430594728.SGD","BK4550","PTGX","IE0002270589.USD","LU0466842654.USD","LU2463526074.USD","LU0889566641.SGD","IE00BVYPNV92.GBP","IE00B42XCP33.USD","LU1057294990.SGD","BK4534","LU1162221912.USD","LU1074936037.SGD","BK4532","LU1244550494.USD","LU2089984988.USD","IE00B19Z3B42.SGD","LU0345769631.USD","IE00B19Z3581.USD","JNJ","IE00BGHQF631.EUR","LU0289739699.SGD","SG9999002224.SGD","LU1059921491.USD","LU2468319806.SGD","LU0234570918.USD","BK4533","IE0034235303.USD","LU0203347892.USD","LU1023059063.AUD","LU0882574055.USD","IE0009355771.USD","ASH","LU0792757196.USD","IE00BSNM7G36.USD","SG9999001440.SGD","LU0345769128.USD","LU0912757837.SGD","LU1732800096.USD","LU1244550577.SGD","SG9999002232.USD","LU1066051498.USD","LU1718418525.SGD","LU1261432733.SGD","LU1894683348.USD","IE00BDGV0183.EUR","IE000M9KFDE8.USD","BK4581"],"gpt_icon":0},{"id":"2490884580","title":"Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2490884580","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490884580?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:01","pubTimestamp":1733778060,"startTime":"0","endTime":"0","summary":"All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2994080/24675/en/Fate-Therapeutics-Presents-New-Phase-1-Clinical-Data-of-FT819-Off-the-shelf-CAR-T-cell-Product-Candidate-for-Systemic-Lupus-Erythematosus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4109","CAR","IE00B66KJ199.SGD","BK4022","LU2463526074.USD","BK4139","IE0031619046.USD","IE00B19Z4B17.USD","BK4006","BK4077","CRS","FATE","SLE","ASH","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2490709297","title":"Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse","url":"https://stock-news.laohu8.com/highlight/detail?id=2490709297","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490709297?lang=en_us&edition=fundamental","pubTime":"2024-12-10 02:38","pubTimestamp":1733769480,"startTime":"0","endTime":"0","summary":"BVd, belantamab mafodotin, bortezomib, and dexamethasone; DVd, daratumumab, bortezomib, and dexamethasone; HR, hazard ratio; ITT, intention to treat; NR, not reached; OS, overall survival; R-ISS, Revised International Staging System. a Two patients in the ITT population were randomized, not treated, rescreened, and rerandomized. They are counted as 4 unique patients in this output. b CIs were estimated using the Brookmeyer-Crowley method. c HRs were estimated using a Cox proportional hazards model stratified by the number of lines of prior therapy , prior bortezomib , and R-ISS stage at screening , with a covariate of treatment. d P value is from a 1-sided stratified log-rank test. At 171 actual events , OS was declared significant if the P value was <.00112. gsk=\"\">. DREAMM-7 trial shows sustained overall survival benefit for belantamab mafodotin combination versus daratumumab combination; benefit seen early and maintained through follow-up. With a median follow up of 39.4 months, the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0kmbDmWYQ7Nff3a4wY6Y4A--~B/aD0yNzA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cb23b28355509679b78dec62cbbaab97","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0kmbDmWYQ7Nff3a4wY6Y4A--~B/aD0yNzA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cb23b28355509679b78dec62cbbaab97"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/belantamab-mafodotin-shows-significant-overall-183800130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GSK.UK","BK4532","BK4588","BK4097","BK4211","GSK","BK4007","LU1829250122.USD","PFS","LU2463526074.USD","BK4195","BK4585","OS","BK4109","ASH"],"gpt_icon":0},{"id":"2490705580","title":"Crispr Therapeutics presents data on CTX112 at ASH Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490705580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490705580?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:25","pubTimestamp":1733765107,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (CRSP) presented data from the Company’s ongoing Phase 1/2 dose escalation clinical trial evaluating the safety and efficacy of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-presents-data-on-ctx112-at-ash-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-presents-data-on-ctx112-at-ash-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4109","CRSP","BK4139","LENZ","BK4585","ASH","LU1861559042.SGD","BK4588","LU2463526074.USD","LU1861558580.USD","BK4556"],"gpt_icon":0},{"id":"2490033037","title":"Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2490033037","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490033037?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:02","pubTimestamp":1733763720,"startTime":"0","endTime":"0","summary":"R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients. SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc., a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initialdata from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome . The data is beingpresented today by Dr. Guillermo Garcia-Manero  at the 66th American Society of Hematology  Annual Meeting and Exposition being held December 7-10, in San Diego, California and virtually.Rigel's open-label, Phase 1b study of R289 is enrolling patients with lower-risk MDS who are R/R to prior therapies . The primary objective of the study is to assess the safety and tolerability of R289 with secondary objectives to assess pre","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/y.2KhNmww8BW2625tcZbsw--~B/aD0yMTY7dz0zNjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6d5d4ea80b797a53937d37e2b5610bea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/y.2KhNmww8BW2625tcZbsw--~B/aD0yMTY7dz0zNjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/6d5d4ea80b797a53937d37e2b5610bea"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rigel-highlights-initial-data-ongoing-170200978.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rigel-highlights-initial-data-ongoing-170200978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","BK4166","LU2065731478.USD","QD","AST","BK4161","IE00B64QTZ34.USD","RBC","ASH","LU1878469433.USD","BK4109","BK4503","BK4599","IE00BLDYK493.USD","BK4563","RIGL","BK4139","LU2463526074.USD"],"gpt_icon":0},{"id":"2490770882","title":"CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490770882","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490770882?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:00","pubTimestamp":1733763600,"startTime":"0","endTime":"0","summary":"-Preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993974/0/en/CRISPR-Therapeutics-Presents-Data-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","LU1861559042.SGD","IE0031619046.USD","AFG","IE00B7SZL793.SGD","CAR","BK4139","BK4556","BK4006","LU2463526074.USD","ASH","SLE","BK4077","BK4022","BK4107","IE00B19Z4B17.USD","BK4094","FL","BK4585","IE00B66KJ199.SGD","BK4230","CRS","CRSP","BK4109","LENZ","BK4588","LU1861558580.USD"],"gpt_icon":0},{"id":"2490708811","title":"Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490708811","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490708811?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:00","pubTimestamp":1733763600,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 9, 2024 Results from Arm 1 of the EPCORE NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993970/0/en/Two-Data-Analyses-from-Clinical-Trials-Show-Epcoritamab-DuoBody-CD3xCD20-Induces-Durable-Complete-Responses-as-Monotherapy-and-Combination-Treatment-in-Patients-With-Diffuse-Large-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ASH","BK4109","CR","BK4093","BK4094","LU2463526074.USD","FL","IPI","BK4161","BK4585"],"gpt_icon":0},{"id":"2490708807","title":"Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2490708807","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490708807?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:00","pubTimestamp":1733763600,"startTime":"0","endTime":"0","summary":"TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly Active Across AML Populations, with Favorable SafetyTUS-based therapies are act","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993973/35575/en/Aptose-Clinical-Data-Featured-in-Poster-Presentation-at-the-2024-ASH-Annual-Meeting-Support-Tuspetinib-Triple-Drug-Therapy-for-Newly-Diagnosed-AML.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APTO","BK4139","BK4109","LU2463526074.USD","ASH"],"gpt_icon":0},{"id":"2490708355","title":"Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490708355","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490708355?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:00","pubTimestamp":1733763600,"startTime":"0","endTime":"0","summary":"Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. ET CAMBRIDGE, Mass., Dec.  09, 2024  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing compa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993977/0/en/Editas-Medicine-Reports-Updated-Clinical-Data-from-the-RUBY-Trial-of-Reni-cel-in-Patients-with-Severe-Sickle-Cell-Disease-at-the-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1861559042.SGD","BK4117","SCD","BK4107","ASH","BK4139","RUBY","CRSP","BK4535","LU2463526074.USD","BK4109","LU1861558580.USD","EDIT","AFG","BK4556","BK4588"],"gpt_icon":0},{"id":"2490670859","title":"Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490670859","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490670859?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:00","pubTimestamp":1733763600,"startTime":"0","endTime":"0","summary":"Additional new profiling of patient responses from the optimized lymphodepletion arm  show consistent P-BCMA-ALLO1 cellular expansion and persistence across subgroups. New preclinical data supports P-CD19CD20-ALLO1's strong anti-cancer profile and the ongoing Phase 1 clinical trial. Case study demonstrates reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in patient with relapsed multiple myeloma, highlighting potential of TSCM-based CAR-T therapies to deliver a strong anti-myeloma response with long-term remission and CAR-T cell persistence. P-BCMA-ALLO1 Phase 1 DataThe poster presentation will highlight Phase 1 clinical data first presented at the 21stInternational Myeloma Society Annual Meeting in September 2024. The data showed a 91% overall response rate  in Arm C , including a 100% ORR in B-cell maturation antigen -nave patients, and an 86% ORR in those who had received at least one prior BCMA- and/or G protein-coupled re","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0ZbecZcTygdfn10jwwgw3w--~B/aD0yOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f05f1549db26db37f15a45f2f462010","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0ZbecZcTygdfn10jwwgw3w--~B/aD0yOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f05f1549db26db37f15a45f2f462010"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/poseida-therapeutics-highlights-positive-interim-170000690.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poseida-therapeutics-highlights-positive-interim-170000690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2463526074.USD","BK4107","AFG","EMD","IE00B7SZL793.SGD","PSTX","IE00B66KJ199.SGD","BK4006","CAR","ASH","BK4117","BK4022","BK4139","LENZ","IE0031619046.USD","BK4109","BK4230","CRS","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2490083397","title":"Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490083397","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490083397?lang=en_us&edition=fundamental","pubTime":"2024-12-10 01:00","pubTimestamp":1733763600,"startTime":"0","endTime":"0","summary":"Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement h","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993966/0/en/Disc-Medicine-Presents-Positive-Clinical-and-Translational-Data-Across-Portfolio-at-the-66th-American-Society-of-Hematology-ASH-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPP","BK4087","AFG","IBD","BK4526","MF","LU2463526074.USD","ASH","BK4539","DSS","IRON","BK4563","BK4113","BK4107","BK4582","BK4117","BK4109"],"gpt_icon":0},{"id":"2490772733","title":"Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2490772733","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490772733?lang=en_us&edition=fundamental","pubTime":"2024-12-10 00:10","pubTimestamp":1733760656,"startTime":"0","endTime":"0","summary":"On Saturday, Beam Therapeutics Inc. revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in patients with sickle cell disease  with severe vaso-occlusive crises .The data were featured at the American Society of Hematology  Annual Meeting and Exposition.Consistent with Beam’spreviously announceddata, updated data from seven patients treated with investigational base-editing therapy BEAM-101 demonstrated robust and durable increases in fetal hemoglobin  and reductions in sickle hemoglobin , rapid neutrophil and platelet engraftment, and normalized or improved markers of hemolysis.Rapid and Sustained Increases in Protective Fetal Hemoglobin : All patients achieved endogenous HbF levels exceeding 60% and reduction in corresponding sickle hemoglobin  below 40% that was durable. A pancellular distribution of HbF was observed after the elimination of transfused blood.In November, the company said that one patient died due to respiratory failure likely related to ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dMxhokG1esN_81MEZrtYTA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7f6bc0c170023f511e362a61f78b2306","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dMxhokG1esN_81MEZrtYTA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7f6bc0c170023f511e362a61f78b2306"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-unveils-safety-efficacy-161056166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","BK4585","ASH","BK4588","BK4109","BK4556","LU2463526074.USD","SCD","BK4139","LENZ","BEAM","BK4505"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASH\",params:#limit:5,,,undefined,":[{"date":"2025-04-30","symbol":"ASH","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":1.14,"defaultRemindTime":1746043200000,"name":null,"time":"Post Market","dateTimestamp":1745985600000,"actualEps":null},{"date":"2025-02-28","symbol":"ASH","amount":0.405,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-01","defaultRemindTime":1740753000000,"name":"亚什兰","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-15","payableDate":"2025-03-01","currency":"USD","dateTimestamp":1740718800000,"payDate":"2025-03-15"},{"market":"US","date":"2025-01-28","symbol":"ASH","fiscalQuarterEnding":"2024/12","expectedEps":0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738040400000,"reportTimeType":"post","actualEps":0.28},{"date":"2024-11-29","symbol":"ASH","amount":0.405,"announcedDate":"2024-11-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-01","defaultRemindTime":1732890600000,"name":"亚什兰","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-15","payableDate":"2024-12-01","currency":"USD","dateTimestamp":1732856400000,"payDate":"2024-12-15"},{"market":"US","date":"2024-11-06","symbol":"ASH","fiscalQuarterEnding":"2024/09","expectedEps":1.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"post","actualEps":1.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASH\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-27","recordDate":"2015-05-29","paymentDate":"2015-06-15","value":0.39,"currency":"USD"},{"executeDate":"2015-08-19","recordDate":"2015-08-21","paymentDate":"2015-09-15","value":0.39,"currency":"USD"},{"executeDate":"2015-11-27","recordDate":"2015-12-01","paymentDate":"2015-12-15","value":0.39,"currency":"USD"},{"executeDate":"2016-02-17","recordDate":"2016-02-19","paymentDate":"2016-03-15","value":0.39,"currency":"USD"},{"executeDate":"2016-06-01","recordDate":"2016-06-03","paymentDate":"2016-06-15","value":0.39,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.4545,"hold":0.2727,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4545,"analysts":11,"updateTime":1743048000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ASH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ASH","date":"2025-04-17","current":-106.268673,"percent":0.042184,"low":-152.607239,"twenty":-10.617545,"median":17.86146,"eighty":27.96106,"high":41.666396,"avg":3.080485,"sd":37.618835,"marketCap":2337910812},"quantilePoints":[{"date":"2020-04-24","current":5.830102,"twenty":10.902122,"median":16.855926,"eighty":45.060758,"marketCap":3410609559},{"date":"2020-05-01","current":6.059763,"twenty":10.78415,"median":16.855926,"eighty":45.060758,"marketCap":3544961429},{"date":"2020-05-08","current":-51.569829,"twenty":10.709199,"median":16.855926,"eighty":45.060758,"marketCap":3764597548},{"date":"2020-05-15","current":-48.919702,"twenty":10.615504,"median":16.855926,"eighty":45.060758,"marketCap":3571138223},{"date":"2020-05-22","current":-52.571909,"twenty":9.138439,"median":16.855926,"eighty":45.060758,"marketCap":3837749355},{"date":"2020-05-29","current":-55.619556,"twenty":9.120788,"median":16.855926,"eighty":45.060758,"marketCap":4060227579},{"date":"2020-06-05","current":-59.636156,"twenty":9.07954,"median":16.855926,"eighty":45.060758,"marketCap":4353439368},{"date":"2020-06-12","current":-55.13922,"twenty":9.032533,"median":16.855926,"eighty":45.060758,"marketCap":4025163076},{"date":"2020-06-19","current":-56.936338,"twenty":8.983635,"median":16.855926,"eighty":45.060758,"marketCap":4156352681},{"date":"2020-06-26","current":-55.08953,"twenty":8.930444,"median":16.855926,"eighty":45.060758,"marketCap":4021535714},{"date":"2020-07-02","current":-57.723095,"twenty":8.872607,"median":16.855926,"eighty":45.060758,"marketCap":4213785918},{"date":"2020-07-10","current":-57.093689,"twenty":8.675995,"median":16.855926,"eighty":45.060758,"marketCap":4167839328},{"date":"2020-07-17","current":-63.354616,"twenty":8.557057,"median":16.855926,"eighty":45.060758,"marketCap":4624886983},{"date":"2020-07-24","current":-64.439512,"twenty":8.367293,"median":16.855926,"eighty":45.060758,"marketCap":4704084394},{"date":"2020-07-31","current":-44.748169,"twenty":8.317859,"median":16.855926,"eighty":45.060758,"marketCap":4564313264},{"date":"2020-08-07","current":-47.060277,"twenty":8.104676,"median":16.855926,"eighty":45.060758,"marketCap":4800148210},{"date":"2020-08-14","current":-45.655227,"twenty":7.849302,"median":16.855926,"eighty":45.060758,"marketCap":4656833127},{"date":"2020-08-21","current":-44.599957,"twenty":7.651738,"median":16.855926,"eighty":45.060758,"marketCap":4549195639},{"date":"2020-08-28","current":-44.718527,"twenty":7.25977,"median":16.855926,"eighty":45.060758,"marketCap":4561289739},{"date":"2020-09-04","current":-44.196821,"twenty":6.363575,"median":16.855926,"eighty":45.060758,"marketCap":4508075700},{"date":"2020-09-11","current":-43.260121,"twenty":6.075417,"median":16.855926,"eighty":45.060758,"marketCap":4412532312},{"date":"2020-09-18","current":-42.133709,"twenty":5.834015,"median":16.855926,"eighty":45.060758,"marketCap":4297638363},{"date":"2020-09-25","current":-41.013227,"twenty":5.699102,"median":16.855926,"eighty":45.060758,"marketCap":4183349120},{"date":"2020-10-02","current":-42.044782,"twenty":5.471088,"median":16.855926,"eighty":45.060758,"marketCap":4288567789},{"date":"2020-10-09","current":-44.101965,"twenty":5.216092,"median":16.855926,"eighty":45.060758,"marketCap":4498400420},{"date":"2020-10-16","current":-45.258019,"twenty":4.885092,"median":16.855926,"eighty":45.060758,"marketCap":4616317893},{"date":"2020-10-23","current":-44.754098,"twenty":4.479735,"median":16.855926,"eighty":45.060758,"marketCap":4564917969},{"date":"2020-10-30","current":-41.363007,"twenty":-40.555548,"median":16.855926,"eighty":45.060758,"marketCap":4219026715},{"date":"2020-11-06","current":-44.754098,"twenty":-41.328622,"median":16.855926,"eighty":45.060758,"marketCap":4564917969},{"date":"2020-11-13","current":-9.712181,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4933788013},{"date":"2020-11-20","current":-9.201515,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4674369572},{"date":"2020-11-27","current":-9.108247,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4626989343},{"date":"2020-12-04","current":-8.938913,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4540967808},{"date":"2020-12-11","current":-9.025329,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4584867159},{"date":"2020-12-18","current":-9.373926,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4761954621},{"date":"2020-12-24","current":-9.457494,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4804407095},{"date":"2020-12-31","current":-9.455107,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4803194167},{"date":"2021-01-08","current":-10.356446,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":5261074419},{"date":"2021-01-15","current":-10.145138,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":5153730307},{"date":"2021-01-22","current":-10.225125,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":5194363389},{"date":"2021-01-29","current":-9.549419,"twenty":-41.685517,"median":16.84568,"eighty":45.060758,"marketCap":4851104816},{"date":"2021-02-05","current":-10.650636,"twenty":-41.685517,"median":16.798842,"eighty":45.060758,"marketCap":5154907958},{"date":"2021-02-12","current":-10.819853,"twenty":-41.685517,"median":16.763713,"eighty":45.060758,"marketCap":5236808932},{"date":"2021-02-19","current":-10.931411,"twenty":-41.685517,"median":16.727121,"eighty":45.060758,"marketCap":5290802907},{"date":"2021-02-26","current":-10.544092,"twenty":-41.685517,"median":16.708151,"eighty":45.060758,"marketCap":5103340678},{"date":"2021-03-05","current":-10.893807,"twenty":-41.766144,"median":16.655852,"eighty":45.067329,"marketCap":5272602691},{"date":"2021-03-12","current":-11.366361,"twenty":-41.766144,"median":16.626772,"eighty":45.067329,"marketCap":5501318743},{"date":"2021-03-19","current":-11.074305,"twenty":-41.766144,"median":16.605449,"eighty":45.067329,"marketCap":5359963729},{"date":"2021-03-26","current":-11.298674,"twenty":-41.685517,"median":16.565507,"eighty":45.060758,"marketCap":5468558354},{"date":"2021-04-01","current":-11.32625,"twenty":-41.685517,"median":16.544159,"eighty":45.032615,"marketCap":5481905179},{"date":"2021-04-09","current":-11.130711,"twenty":-41.766144,"median":16.513421,"eighty":45.025182,"marketCap":5387264054},{"date":"2021-04-16","current":-11.373882,"twenty":-41.766144,"median":16.49824,"eighty":44.88663,"marketCap":5504958787},{"date":"2021-04-23","current":-11.615799,"twenty":-41.766144,"median":16.458163,"eighty":44.798223,"marketCap":5622046845},{"date":"2021-04-30","current":37.652621,"twenty":-41.766144,"median":16.458163,"eighty":44.763306,"marketCap":5233714269},{"date":"2021-05-07","current":38.556703,"twenty":-41.766144,"median":16.48927,"eighty":44.763306,"marketCap":5359381692},{"date":"2021-05-14","current":38.897371,"twenty":-41.766144,"median":16.508117,"eighty":44.763306,"marketCap":5406734634},{"date":"2021-05-21","current":38.897371,"twenty":-41.766144,"median":16.532217,"eighty":44.763306,"marketCap":5406734634},{"date":"2021-05-28","current":41.421813,"twenty":-41.766144,"median":16.539302,"eighty":44.763306,"marketCap":5757632076},{"date":"2021-06-04","current":41.177231,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5723635092},{"date":"2021-06-11","current":40.923913,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5688423930},{"date":"2021-06-18","current":38.067538,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5291387724},{"date":"2021-06-25","current":38.72267,"twenty":-41.766144,"median":16.559996,"eighty":44.763306,"marketCap":5382451074},{"date":"2021-07-02","current":38.32959,"twenty":-41.766144,"median":16.589527,"eighty":44.763306,"marketCap":5327813064},{"date":"2021-07-09","current":38.399471,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5337526488},{"date":"2021-07-16","current":37.713766,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5242213515},{"date":"2021-07-23","current":38.233504,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5314457106},{"date":"2021-07-30","current":28.544675,"twenty":-41.766144,"median":16.63409,"eighty":44.763306,"marketCap":5166586254},{"date":"2021-08-06","current":28.329928,"twenty":-41.766144,"median":16.642592,"eighty":44.763306,"marketCap":5127716909},{"date":"2021-08-13","current":29.118455,"twenty":-41.766144,"median":16.707431,"eighty":44.763306,"marketCap":5270440286},{"date":"2021-08-20","current":28.051427,"twenty":-41.766144,"median":16.798988,"eighty":44.763306,"marketCap":5077308227},{"date":"2021-08-27","current":29.259383,"twenty":-41.766144,"median":16.876011,"eighty":44.763306,"marketCap":5295948294},{"date":"2021-09-03","current":31.51759,"twenty":-41.685517,"median":16.928602,"eighty":44.762757,"marketCap":5704683753},{"date":"2021-09-10","current":31.051184,"twenty":-41.685517,"median":16.94157,"eighty":44.762757,"marketCap":5620264394},{"date":"2021-09-17","current":30.272724,"twenty":-41.685517,"median":16.987677,"eighty":44.762757,"marketCap":5479363017},{"date":"2021-09-24","current":31.121649,"twenty":-41.685517,"median":16.987677,"eighty":44.762757,"marketCap":5633018398},{"date":"2021-10-01","current":30.59149,"twenty":-41.685517,"median":19.684212,"eighty":44.762757,"marketCap":5537059701},{"date":"2021-10-08","current":31.071317,"twenty":-41.685517,"median":19.787677,"eighty":44.762757,"marketCap":5623908395},{"date":"2021-10-15","current":32.124923,"twenty":-41.685517,"median":19.83941,"eighty":44.762757,"marketCap":5814611120},{"date":"2021-10-22","current":32.826209,"twenty":-41.685517,"median":19.917009,"eighty":44.762757,"marketCap":5941543826},{"date":"2021-10-29","current":32.21552,"twenty":-41.604889,"median":19.999764,"eighty":44.762207,"marketCap":5831009125},{"date":"2021-11-05","current":32.916806,"twenty":-41.604889,"median":20.15896,"eighty":44.762207,"marketCap":5957941831},{"date":"2021-11-12","current":29.342491,"twenty":-41.604889,"median":20.28364,"eighty":44.762207,"marketCap":6455347984},{"date":"2021-11-19","current":30.162391,"twenty":-41.604889,"median":20.500749,"eighty":44.762207,"marketCap":6635726039},{"date":"2021-11-26","current":26.923508,"twenty":-41.604889,"median":20.528215,"eighty":44.762207,"marketCap":5923171764},{"date":"2021-12-03","current":26.411959,"twenty":-41.604889,"median":20.552965,"eighty":44.762207,"marketCap":5810630932},{"date":"2021-12-10","current":27.165993,"twenty":-41.604889,"median":20.676932,"eighty":44.762207,"marketCap":5976518382},{"date":"2021-12-17","current":26.837476,"twenty":-41.604889,"median":20.708356,"eighty":44.762207,"marketCap":5904244736},{"date":"2021-12-23","current":26.982334,"twenty":-41.604889,"median":20.728755,"eighty":44.762207,"marketCap":5936113430},{"date":"2021-12-31","current":27.848893,"twenty":-41.604889,"median":20.764302,"eighty":44.762207,"marketCap":6126756513},{"date":"2022-01-07","current":26.876277,"twenty":-41.524262,"median":20.796751,"eighty":44.761658,"marketCap":5912780993},{"date":"2022-01-14","current":27.341891,"twenty":-41.524262,"median":20.868148,"eighty":44.761658,"marketCap":6015216083},{"date":"2022-01-21","current":25.013821,"twenty":-41.524262,"median":20.917445,"eighty":44.761658,"marketCap":5503040636},{"date":"2022-01-28","current":24.677544,"twenty":-41.524262,"median":20.980342,"eighty":44.761658,"marketCap":5429059738},{"date":"2022-02-04","current":25.572734,"twenty":-41.443634,"median":21.023702,"eighty":44.761108,"marketCap":5421419569},{"date":"2022-02-11","current":25.553938,"twenty":-41.443634,"median":21.065338,"eighty":44.761108,"marketCap":5417434905},{"date":"2022-02-18","current":25.494866,"twenty":-41.443634,"median":21.115412,"eighty":44.761108,"marketCap":5404911676},{"date":"2022-02-25","current":25.29617,"twenty":-41.443634,"median":21.157984,"eighty":44.761108,"marketCap":5362788089},{"date":"2022-03-04","current":23.572347,"twenty":-41.443634,"median":21.240692,"eighty":44.761108,"marketCap":4997337504},{"date":"2022-03-11","current":23.66901,"twenty":-41.443634,"median":21.332705,"eighty":44.761108,"marketCap":5017830061},{"date":"2022-03-18","current":25.352557,"twenty":-41.443634,"median":21.402701,"eighty":44.761108,"marketCap":5374742080},{"date":"2022-03-25","current":26.448071,"twenty":-41.443634,"median":21.507199,"eighty":44.761108,"marketCap":5606991049},{"date":"2022-04-01","current":26.544734,"twenty":-41.443634,"median":21.611248,"eighty":44.761108,"marketCap":5627483605},{"date":"2022-04-08","current":26.703154,"twenty":-41.443634,"median":21.681627,"eighty":44.761108,"marketCap":5661068628},{"date":"2022-04-14","current":28.520955,"twenty":-41.443634,"median":21.86021,"eighty":44.761108,"marketCap":6046442530},{"date":"2022-04-22","current":27.734226,"twenty":-41.443634,"median":22.114023,"eighty":44.761108,"marketCap":5879655893},{"date":"2022-04-29","current":5.98168,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5724467780},{"date":"2022-05-06","current":5.79477,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5545595204},{"date":"2022-05-13","current":5.627805,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5385809640},{"date":"2022-05-20","current":5.695617,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5450705483},{"date":"2022-05-27","current":6.155649,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5890955748},{"date":"2022-06-03","current":6.053281,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5792989652},{"date":"2022-06-10","current":5.809521,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5559711268},{"date":"2022-06-17","current":5.398352,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5166223136},{"date":"2022-06-24","current":5.835537,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5584608729},{"date":"2022-07-01","current":5.86325,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5611129938},{"date":"2022-07-08","current":5.737128,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5490431377},{"date":"2022-07-15","current":5.58499,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5344835356},{"date":"2022-07-22","current":5.922634,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5667961098},{"date":"2022-07-29","current":5.951187,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5439385116},{"date":"2022-08-05","current":6.14725,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5618586516},{"date":"2022-08-12","current":6.304219,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5762055916},{"date":"2022-08-19","current":6.275787,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5736069006},{"date":"2022-08-26","current":6.098679,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5574192212},{"date":"2022-09-02","current":5.884253,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5378207598},{"date":"2022-09-09","current":6.054846,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5534129059},{"date":"2022-09-16","current":5.848121,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5345182567},{"date":"2022-09-23","current":5.752755,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5258018139},{"date":"2022-09-30","current":5.625403,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5141618438},{"date":"2022-10-07","current":5.617703,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5134580316},{"date":"2022-10-14","current":5.641396,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5156236075},{"date":"2022-10-21","current":5.922755,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5413398206},{"date":"2022-10-28","current":6.27401,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5734444824},{"date":"2022-11-04","current":5.909724,"twenty":-41.524262,"median":21.695313,"eighty":44.761658,"marketCap":5401487538},{"date":"2022-11-11","current":6.292902,"twenty":-41.524262,"median":21.556282,"eighty":44.761658,"marketCap":5833519919},{"date":"2022-11-18","current":6.534105,"twenty":-41.524262,"median":9.134384,"eighty":44.761658,"marketCap":6057115624},{"date":"2022-11-25","current":6.524573,"twenty":-41.524262,"median":9.120072,"eighty":44.761658,"marketCap":6048278877},{"date":"2022-12-02","current":6.634386,"twenty":-41.524262,"median":9.077138,"eighty":44.761658,"marketCap":6150076230},{"date":"2022-12-09","current":6.425327,"twenty":-41.524262,"median":9.031818,"eighty":44.761658,"marketCap":5956278049},{"date":"2022-12-16","current":6.216944,"twenty":-41.524262,"median":8.981727,"eighty":44.761658,"marketCap":5763107329},{"date":"2022-12-23","current":6.332842,"twenty":-41.524262,"median":8.929251,"eighty":44.761658,"marketCap":5870544977},{"date":"2022-12-30","current":6.29421,"twenty":-41.524262,"median":8.870812,"eighty":44.761658,"marketCap":5834732428},{"date":"2023-01-06","current":6.238017,"twenty":-41.524262,"median":8.723665,"eighty":44.669031,"marketCap":5782641447},{"date":"2023-01-13","current":6.570492,"twenty":-41.524262,"median":8.558011,"eighty":44.528495,"marketCap":6090846415},{"date":"2023-01-20","current":6.436448,"twenty":-41.524262,"median":8.531792,"eighty":44.433823,"marketCap":5966587722},{"date":"2023-01-27","current":6.301234,"twenty":-41.524262,"median":8.3296,"eighty":44.14834,"marketCap":5841243800},{"date":"2023-02-03","current":6.219087,"twenty":-40.702575,"median":8.3296,"eighty":44.14834,"marketCap":5715340826},{"date":"2023-02-10","current":6.142315,"twenty":-11.558641,"median":8.3296,"eighty":44.14834,"marketCap":5644787763},{"date":"2023-02-17","current":6.10452,"twenty":-11.342294,"median":8.3296,"eighty":44.14834,"marketCap":5610053948},{"date":"2023-02-24","current":6.038378,"twenty":-11.297421,"median":8.3296,"eighty":44.14834,"marketCap":5549269770},{"date":"2023-03-03","current":6.122827,"twenty":-11.1811,"median":8.3296,"eighty":44.14834,"marketCap":5626878140},{"date":"2023-03-10","current":5.75019,"twenty":-11.13773,"median":8.3296,"eighty":44.14834,"marketCap":5284424426},{"date":"2023-03-17","current":5.610229,"twenty":-11.066032,"median":8.3296,"eighty":44.14834,"marketCap":5155800765},{"date":"2023-03-24","current":5.809835,"twenty":-10.976285,"median":8.3296,"eighty":44.14834,"marketCap":5339238729},{"date":"2023-03-31","current":6.065544,"twenty":-10.897567,"median":8.324965,"eighty":44.139273,"marketCap":5574234700},{"date":"2023-04-06","current":5.988772,"twenty":-10.820856,"median":8.324965,"eighty":44.139273,"marketCap":5503681637},{"date":"2023-04-14","current":6.134638,"twenty":-10.775982,"median":8.3296,"eighty":44.14834,"marketCap":5637732457},{"date":"2023-04-21","current":6.151764,"twenty":-10.730374,"median":8.3296,"eighty":44.14834,"marketCap":5653471217},{"date":"2023-04-27","current":5.856489,"twenty":-10.606264,"median":8.340928,"eighty":44.166474,"marketCap":5382113282},{"date":"2023-05-05","current":20.861975,"twenty":-10.43882,"median":8.452838,"eighty":44.175541,"marketCap":4693944269},{"date":"2023-05-12","current":20.287633,"twenty":-10.336151,"median":8.558011,"eighty":44.182524,"marketCap":4564717446},{"date":"2023-05-19","current":21.14158,"twenty":-10.102877,"median":8.693871,"eighty":44.189507,"marketCap":4756855455},{"date":"2023-05-26","current":20.227136,"twenty":-9.78508,"median":8.870812,"eighty":44.196491,"marketCap":4551105489},{"date":"2023-06-02","current":19.892072,"twenty":-9.536436,"median":8.929251,"eighty":44.196491,"marketCap":4475716188},{"date":"2023-06-09","current":20.206194,"twenty":-9.454384,"median":8.98113,"eighty":44.203474,"marketCap":4546393658},{"date":"2023-06-16","current":20.073565,"twenty":-9.376314,"median":9.018699,"eighty":44.210457,"marketCap":4516552059},{"date":"2023-06-23","current":19.475569,"twenty":-9.301666,"median":9.056863,"eighty":44.224123,"marketCap":4382003099},{"date":"2023-06-29","current":19.508145,"twenty":-9.246426,"median":9.092642,"eighty":44.237789,"marketCap":4389332615},{"date":"2023-07-05","current":20.315555,"twenty":-9.193781,"median":9.114705,"eighty":44.251456,"marketCap":4570999888},{"date":"2023-07-14","current":20.455165,"twenty":-9.060547,"median":9.163604,"eighty":44.278788,"marketCap":4602412096},{"date":"2023-07-20","current":21.216038,"twenty":-8.93818,"median":19.183552,"eighty":44.278788,"marketCap":4773608633},{"date":"2023-07-28","current":19.591649,"twenty":4.319692,"median":19.750135,"eighty":44.283744,"marketCap":4682404042},{"date":"2023-08-04","current":19.289348,"twenty":4.38581,"median":19.591649,"eighty":44.129229,"marketCap":4610154209},{"date":"2023-08-11","current":19.13927,"twenty":4.38581,"median":19.482306,"eighty":43.956729,"marketCap":4574285498},{"date":"2023-08-18","current":18.466062,"twenty":4.38581,"median":19.154278,"eighty":43.542383,"marketCap":4413388708},{"date":"2023-08-25","current":18.088722,"twenty":4.38581,"median":18.641868,"eighty":43.319191,"marketCap":4323204519},{"date":"2023-08-31","current":18.781226,"twenty":4.38581,"median":18.466062,"eighty":42.973946,"marketCap":4488713001},{"date":"2023-09-08","current":17.87218,"twenty":4.380867,"median":18.294543,"eighty":42.623722,"marketCap":4271451093},{"date":"2023-09-13","current":17.293307,"twenty":4.378395,"median":18.166977,"eighty":42.388429,"marketCap":4133100350},{"date":"2023-09-22","current":18.005107,"twenty":4.319692,"median":17.86146,"eighty":42.077012,"marketCap":4303220523},{"date":"2023-09-29","current":17.479833,"twenty":4.263461,"median":17.50556,"eighty":41.816324,"marketCap":4177680034},{"date":"2023-10-06","current":17.087485,"twenty":4.263461,"median":17.293307,"eighty":41.73771,"marketCap":4083908975},{"date":"2023-10-13","current":16.418565,"twenty":4.263461,"median":16.945983,"eighty":41.577207,"marketCap":3924037005},{"date":"2023-10-20","current":16.294214,"twenty":4.207231,"median":16.495748,"eighty":41.332109,"marketCap":3894317216},{"date":"2023-10-27","current":16.257767,"twenty":-1.056217,"median":16.28671,"eighty":41.192954,"marketCap":3885606243},{"date":"2023-11-03","current":16.332806,"twenty":-6.207204,"median":16.153784,"eighty":40.948113,"marketCap":3903540598},{"date":"2023-11-10","current":15.616718,"twenty":-6.207204,"median":15.881499,"eighty":40.817223,"marketCap":3732395605},{"date":"2023-11-17","current":16.390693,"twenty":-6.207204,"median":15.574911,"eighty":40.340898,"marketCap":3917375673},{"date":"2023-11-24","current":22.827913,"twenty":-6.207204,"median":15.574911,"eighty":39.96161,"marketCap":4063368468},{"date":"2023-12-01","current":23.015098,"twenty":-8.782697,"median":15.533103,"eighty":39.312288,"marketCap":4096687371},{"date":"2023-12-07","current":23.654406,"twenty":-6.207204,"median":15.574911,"eighty":38.926597,"marketCap":4210484243},{"date":"2023-12-15","current":24.893249,"twenty":-8.782697,"median":15.533103,"eighty":38.72267,"marketCap":4430998377},{"date":"2023-12-22","current":24.325418,"twenty":-8.782697,"median":15.533103,"eighty":38.648421,"marketCap":4329924480},{"date":"2023-12-29","current":24.225549,"twenty":-8.789917,"median":12.47951,"eighty":38.641433,"marketCap":4312147664},{"date":"2024-01-05","current":22.661874,"twenty":-8.797137,"median":9.425916,"eighty":38.597758,"marketCap":4033813516},{"date":"2024-01-12","current":23.423737,"twenty":-8.797137,"median":9.425916,"eighty":38.470225,"marketCap":4169425227},{"date":"2024-01-19","current":22.447867,"twenty":-8.804357,"median":9.30281,"eighty":38.332211,"marketCap":3995720339},{"date":"2024-01-26","current":22.718942,"twenty":-8.797137,"median":9.425916,"eighty":38.217781,"marketCap":4043971696},{"date":"2024-02-02","current":28.85349,"twenty":-8.797137,"median":9.425916,"eighty":38.049194,"marketCap":4731972377},{"date":"2024-02-09","current":27.918791,"twenty":-8.797137,"median":9.425916,"eighty":37.903318,"marketCap":4578681720},{"date":"2024-02-16","current":28.325049,"twenty":-8.797137,"median":9.425916,"eighty":37.631656,"marketCap":4645308051},{"date":"2024-02-23","current":28.413632,"twenty":-8.797137,"median":9.425916,"eighty":37.11978,"marketCap":4659835597},{"date":"2024-03-01","current":28.603015,"twenty":-8.789917,"median":12.47951,"eighty":32.879225,"marketCap":4690894489},{"date":"2024-03-08","current":29.339167,"twenty":-8.789917,"median":12.47951,"eighty":32.536971,"marketCap":4811623405},{"date":"2024-03-15","current":29.363604,"twenty":-8.789917,"median":12.47951,"eighty":32.258469,"marketCap":4815631004},{"date":"2024-03-22","current":29.357495,"twenty":-8.789917,"median":12.47951,"eighty":31.941046,"marketCap":4814629104},{"date":"2024-03-28","current":29.81568,"twenty":-8.789917,"median":12.47951,"eighty":31.40619,"marketCap":4889771583},{"date":"2024-04-05","current":29.122292,"twenty":-8.797137,"median":9.425916,"eighty":31.117622,"marketCap":4776055965},{"date":"2024-04-12","current":29.372767,"twenty":-8.797137,"median":9.425916,"eighty":31.051184,"marketCap":4817133853},{"date":"2024-04-19","current":29.168111,"twenty":-8.797137,"median":9.425916,"eighty":30.606254,"marketCap":4783570213},{"date":"2024-04-26","current":29.079528,"twenty":-8.789917,"median":12.47951,"eighty":30.256618,"marketCap":4769042667},{"date":"2024-05-03","current":24.879315,"twenty":-8.789917,"median":12.47951,"eighty":29.945905,"marketCap":4801707860},{"date":"2024-05-10","current":25.416952,"twenty":-8.789917,"median":12.47951,"eighty":29.757033,"marketCap":4905471669},{"date":"2024-05-17","current":25.614345,"twenty":-8.789917,"median":12.47951,"eighty":29.613467,"marketCap":4943568527},{"date":"2024-05-24","current":25.463703,"twenty":-8.789917,"median":12.47951,"eighty":29.5169,"marketCap":4914494609},{"date":"2024-05-31","current":25.87667,"twenty":-8.789917,"median":12.47951,"eighty":29.365437,"marketCap":4994197245},{"date":"2024-06-07","current":26.035104,"twenty":-8.789917,"median":12.47951,"eighty":29.342276,"marketCap":5024774986},{"date":"2024-06-14","current":25.292282,"twenty":-8.797137,"median":9.425916,"eighty":29.274986,"marketCap":4881410496},{"date":"2024-06-21","current":25.066319,"twenty":-8.804357,"median":9.30281,"eighty":29.230424,"marketCap":4837799620},{"date":"2024-06-28","current":24.487127,"twenty":-8.826676,"median":9.172548,"eighty":29.168722,"marketCap":4726015420},{"date":"2024-07-05","current":24.193634,"twenty":-8.826676,"median":9.172548,"eighty":29.132067,"marketCap":4669371408},{"date":"2024-07-12","current":24.601407,"twenty":-8.826676,"median":9.172548,"eighty":29.097856,"marketCap":4748071495},{"date":"2024-07-15","current":24.596212,"twenty":-8.826676,"median":9.172548,"eighty":29.090525,"marketCap":4747068946},{"date":"2024-08-02","current":24.957234,"twenty":-8.929025,"median":9.114705,"eighty":28.735731,"marketCap":4816746093},{"date":"2024-08-09","current":27.237695,"twenty":-8.929025,"median":9.114705,"eighty":28.677936,"marketCap":4058416549},{"date":"2024-08-16","current":27.91282,"twenty":-8.929025,"median":9.114705,"eighty":28.593851,"marketCap":4159010197},{"date":"2024-08-23","current":28.407693,"twenty":-8.929025,"median":9.114705,"eighty":28.535286,"marketCap":4232746318},{"date":"2024-08-30","current":29.413827,"twenty":-8.929025,"median":9.114705,"eighty":28.535286,"marketCap":4382660153},{"date":"2024-09-06","current":28.273324,"twenty":-8.929025,"median":9.114705,"eighty":28.515633,"marketCap":4212725252},{"date":"2024-09-13","current":27.91282,"twenty":-8.929025,"median":9.114705,"eighty":28.437936,"marketCap":4159010197},{"date":"2024-09-20","current":28.840298,"twenty":-8.929025,"median":9.114705,"eighty":28.414125,"marketCap":4297204384},{"date":"2024-09-27","current":28.584668,"twenty":-8.929025,"median":9.114705,"eighty":28.410315,"marketCap":4259115526},{"date":"2024-10-04","current":27.693241,"twenty":-8.929025,"median":9.114705,"eighty":28.328952,"marketCap":4126292846},{"date":"2024-10-11","current":27.781728,"twenty":-8.929025,"median":9.114705,"eighty":28.174035,"marketCap":4139477450},{"date":"2024-10-18","current":28.768197,"twenty":-8.929025,"median":9.114705,"eighty":28.155826,"marketCap":4286461373},{"date":"2024-10-25","current":27.847274,"twenty":-8.929025,"median":9.114705,"eighty":28.143107,"marketCap":4149243823},{"date":"2024-10-31","current":28.55845,"twenty":-8.929025,"median":9.114705,"eighty":28.102675,"marketCap":4255208977},{"date":"2024-11-08","current":23.317939,"twenty":-8.93818,"median":9.109339,"eighty":27.987673,"marketCap":3940731747},{"date":"2024-11-15","current":22.552233,"twenty":-8.93818,"median":9.109339,"eighty":27.96198,"marketCap":3811327297},{"date":"2024-11-22","current":21.642415,"twenty":-8.93818,"median":9.127228,"eighty":27.96083,"marketCap":3657568070},{"date":"2024-11-29","current":21.759491,"twenty":-8.93818,"median":9.172548,"eighty":27.96083,"marketCap":3677353987},{"date":"2024-12-06","current":21.310698,"twenty":-8.93818,"median":16.14628,"eighty":27.96083,"marketCap":3601507972},{"date":"2024-12-13","current":20.66399,"twenty":-8.93818,"median":16.326374,"eighty":27.96083,"marketCap":3492214336},{"date":"2024-12-20","current":20.056308,"twenty":-8.93818,"median":16.418565,"eighty":27.96083,"marketCap":3389516005},{"date":"2024-12-27","current":20.109271,"twenty":-8.93818,"median":16.564355,"eighty":27.96083,"marketCap":3398466777},{"date":"2025-01-03","current":19.440263,"twenty":-8.93818,"median":16.920255,"eighty":27.96083,"marketCap":3285404395},{"date":"2025-01-10","current":19.6399,"twenty":-8.938327,"median":17.089629,"eighty":27.96106,"marketCap":3319143109},{"date":"2025-01-17","current":19.75157,"twenty":-8.938327,"median":17.49484,"eighty":27.96106,"marketCap":3338015281},{"date":"2025-01-24","current":20.086579,"twenty":-8.938327,"median":17.759622,"eighty":27.96106,"marketCap":3394631794},{"date":"2025-01-31","current":-136.701619,"twenty":-9.032373,"median":17.86146,"eighty":27.96106,"marketCap":3007435623},{"date":"2025-02-07","current":-139.725612,"twenty":-9.144874,"median":17.86146,"eighty":27.96106,"marketCap":3073963459},{"date":"2025-02-14","current":-139.361017,"twenty":-9.245709,"median":17.86146,"eighty":27.96106,"marketCap":3065942372},{"date":"2025-02-21","current":-140.326121,"twenty":-9.301666,"median":17.86146,"eighty":27.96106,"marketCap":3087174660},{"date":"2025-02-28","current":-131.897546,"twenty":-9.377985,"median":17.86146,"eighty":27.96106,"marketCap":2901746013},{"date":"2025-03-07","current":-127.90845,"twenty":-9.455107,"median":17.87218,"eighty":27.96129,"marketCap":2813985889},{"date":"2025-03-14","current":-119.994597,"twenty":-9.579026,"median":17.87218,"eighty":27.96129,"marketCap":2639881128},{"date":"2025-03-21","current":-119.823023,"twenty":-9.954842,"median":17.87218,"eighty":27.96129,"marketCap":2636106499},{"date":"2025-03-28","current":-128.144364,"twenty":-10.210799,"median":17.87218,"eighty":27.96129,"marketCap":2819176004},{"date":"2025-04-04","current":-113.839378,"twenty":-10.377935,"median":17.87218,"eighty":27.96129,"marketCap":2504466314},{"date":"2025-04-11","current":-104.209785,"twenty":-10.499986,"median":17.86146,"eighty":27.96106,"marketCap":2292615264},{"date":"2025-04-17","current":-106.268673,"twenty":-10.617545,"median":17.86146,"eighty":27.96106,"marketCap":2337910812}],"updateTime":1745038071831}}}